Astec LifeSciences Limited has announced its financial results for the fourth quarter and the financial year ending 31st March 2026, showcasing a robust performance. The company reported a consolidated total income of ₹161.3 crore for Q4 FY26, marking a 34% increase from ₹120.3 crore in the same quarter of the previous year.
The company’s consolidated EBITDA for the quarter stood at ₹11.8 crore, significantly up from ₹6.3 crore in Q4 FY25, indicating an 87% growth. Despite this, Astec recorded a loss after tax of ₹7.7 crore in Q4 FY26, compared to a loss of ₹16.1 crore in the corresponding quarter last year.
For the full financial year FY26, Astec reported a consolidated total income of ₹453.2 crore, up from ₹386.9 crore in FY25, reflecting a 17.1% growth. The company achieved an EBITDA breakeven of ₹0.5 crore for FY26, a significant improvement from an EBITDA loss of ₹60.6 crore in FY25. However, the company reported a loss after exceptional items and tax of ₹80.9 crore for FY26, compared to a loss of ₹134.7 crore in the previous year.
The exceptional items included a financial impact due to the revised wage definition under the new Labour Codes notified by the Government of India, which accounted for gratuity and long-term compensated absences amounting to ₹1.7 crore and ₹0.4 crore, respectively.
Chairperson Mr. Vishal Sharma highlighted the strong revenue growth driven by improved volumes in both the Enterprise and Contract Manufacturing segments. The company saw a sequential revenue increase of 29% over Q3 FY26, primarily due to Enterprise Volumes. This growth led to a significant margin expansion, contributing to the increased EBITDA.
Astec’s revenue from operations in Q4 FY26 showed a 37.1% increase in the Enterprise category and a 29.5% rise in Contract Manufacturing and New Products. Geographically, export revenues grew by 8% to ₹103.7 crore, while domestic revenues surged by 133.8% to ₹54.9 crore.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).